Skip to content

Startup & venture capital news

Pathos AI raises USD 237 million for oncology drug development

Bristol Myers Squibb leads the Series E.

By /

LinkedInX
Pathos AI: Pathos AI raises USD 237 million for oncology drug development
OncoDaily

Pathos AI announced a USD 237 million Series E on 23 October 2026, led by Bristol Myers Squibb. The New York company develops an artificial intelligence platform for oncology drug discovery and development. Its Foundry system combines clinical data, genomics, biological samples and competitive intelligence to guide portfolio and trial decisions. Existing investors also participated. Pathos will use the financing to expand the platform and advance its oncology pipeline, including the JSKN016 antibody drug conjugate. The new capital is separate from the approximately USD 3 billion post money valuation reported alongside the transaction.

Keep reading

More Funding

All stories